• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BeyondSpring Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    6/4/26 7:30:18 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BYSI alert in real time by email
    Form 8-K
    False000167794000016779402026-06-042026-06-04iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________

    FORM 8-K

    _________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  June 4, 2026

    _______________________________

    BeyondSpring Inc.

    (Exact name of registrant as specified in its charter)

    _______________________________

    Cayman Islands001-38024Not Applicable
    (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

    100 Campus Drive, West Side, 4th Floor, Suite 410

    Florham Park, New Jersey 07932

    (Address of Principal Executive Offices) (Zip Code)

    +1 (646) 305-6387

    (Registrant's telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

    _______________________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Ordinary Shares, par value $0.0001 per shareBYSIThe NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     
     
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On June 4, 2026, BeyondSpring Inc. (the “Company”) announced certain leadership transitions:

     

    (b)       Transition from Chief Executive Officer.

     

    Dr. Lan Huang, the current Chief Executive Officer and Chair of the Board of Directors (the “Board”) of the Company, will transition from her role as Chief Executive Officer, effective July 1, 2026. Dr. Huang will continue to serve the Company in a focused capacity as the Chair of the Board.

     

    In connection with this transition, all of Dr. Huang’s unvested equity and long-term incentive awards will be forfeited effective July 1, 2026.

     

    (c)       Appointment of Chief Executive Officer and Chief Financial Officer.

     

    Mr. Min Qiu, age 43, is appointed Chief Executive Officer of the Company, effective July 1, 2026. Mr. Qiu has been actively involved in the Company’s corporate development for the past five years in the position of Vice General Manager of Dalian Wanchunbulin Pharmaceutical Co., Ltd. (“Wanchunbulin”), a subsidiary of the Company, a role he has held since April 2026 and previously from August 2020 to August 2023. From September 2023 to March 2026, Mr. Qiu worked as an independent advisor specializing in capital markets and investment advisory. He previously served as Board Secretary of Guangyuyuan Chinese Herbal Medicine Co., Ltd. (SH: 600771) and as a healthcare analyst at China Merchants Securities, focused on the China-Japan pharmaceutical sector. He holds a Bachelor of Pharmacy and a Master of Engineering in Technology Management for Innovation from the University of Tokyo.

     

    Ms. Na Li, age 49, is appointed Chief Financial Officer of the Company, effective July 1, 2026. Ms. Li has served as Chief Financial Officer of Wanchunbulin since November 2020. She holds an Accountant Certificate, a CFO Qualification Certificate, and a Shanghai Stock Exchange Board Secretary Qualification Certificate. She previously served as Board Secretary of a Main Board-listed Chinese pharmaceutical company on the Shanghai Stock Exchange and a Third Board-listed company on the Beijing Stock Exchange.

     

    There are no family relationships between Mr. Qiu or Ms. Li and any director or executive officer of the Company that would be required to be disclosed pursuant to Item 401(d) of Regulation S-K or any other arrangements or understandings between Mr. Qiu or Ms. Li and any other person that would be required to be disclosed pursuant to Item 401(b) of Regulation S-K, and there are no transactions between Mr. Qiu or Ms. Li and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

     

    As of the date of this report, the Company has not finalized the employment agreements or compensatory arrangements for Mr. Qiu in connection with his appointment as Chief Executive Officer, or for Ms. Li in connection with her appointment as Chief Financial Officer. The Company will file an amendment to this Current Report on Form 8-K to disclose such compensatory arrangements within four business days after they are determined and finalized.

     

    (d)       Appointment of Vice Chair of the Board.

     

    Dr. Jiangwen Majeti, the current Chair of the Nominating and Corporate Governance Committee of the Board and a member of the Compensation Committee of the Board, is appointed Vice Chair of the Board, effective July 1, 2026.

     

    In connection with this appointment, the Board approved a one-time grant to Dr. Majeti of share options to purchase 100,000 shares of the Company’s ordinary shares which will vest in four equal annual installments following the grant date. The share options will be granted pursuant to the terms and conditions of the Company’s 2017 Omnibus Incentive Plan and the standard form of option agreement.

     

    Item 7.01. Regulation FD Disclosure.

     

    On June 4, 2026, the Company issued a press release relating to the matters described above in Item 5.02. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    The information in this Item 7.01 of Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No. Exhibit
       
    99.1 Press release, dated June 4, 2026.
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     BeyondSpring Inc.
       
      
    Date: June 4, 2026By: /s/ Lan Huang        
      Lan Huang
      Chairperson and Chief Executive Officer
      

     

    Get the next $BYSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BYSI

    DatePrice TargetRatingAnalyst
    12/2/2021$38.00 → $5.00Buy → Hold
    Jefferies
    12/2/2021$45.00 → $5.00Buy → Underperform
    B of A Securities
    12/1/2021Outperform → Mkt Perform
    William Blair
    12/1/2021Buy → Neutral
    H.C. Wainwright
    9/20/2021$100.00 → $65.00Buy
    HC Wainwright & Co.
    9/9/2021$50.00Outperform
    Robert W. Baird
    9/9/2021$50.00Outperform
    Baird
    8/4/2021$100.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $BYSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

    Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully dedicated executive leaderDr. Jiangwen (Jen) Majeti, PhD, MBA, current BeyondSpring Director, appointed Vice Chairman — deepening Board-level governance and providing strategic continuityMin Qiu appointed Chief Executive Officer with a clear mandate: execute DUBLIN-4, extend Plinabulin's scientific optionality, and build BeyondSpring's global partner and investor baseNa Li appointed Chief Financial Officer to strengthen BeyondSpring's financial position and support capital mark

    6/4/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

    Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitorsDurable survival benefit: 12-month OS rate of 78.1% and 24-month OS rate of 58.0% in a patient population with limited treatment optionsGood tolerability and immune activation: Along with increased frequencies of activated CD4+/CD8+ T cells post-treatment, hematology test also showed safety benefit with significantly higher levels of WBCs, neutrophils and platelets. FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company

    6/2/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

    FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada, and BeyondSpring, in patients with 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 through June 2 in Chicago, IL. Presentation details are as follows: Title: A Phase 2 Study of Plinabulin (Plin)/Doceta

    5/18/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    SEC Filings

    View All

    BeyondSpring Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BeyondSpring Inc. (0001677940) (Filer)

    6/4/26 7:30:18 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by BeyondSpring Inc.

    10-Q - BeyondSpring Inc. (0001677940) (Filer)

    5/13/26 4:30:42 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BeyondSpring Inc. (0001677940) (Filer)

    5/13/26 7:00:21 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Huang Lan gifted 260,582 units of Ordinary Shares (SEC Form 4)

    4 - BeyondSpring Inc. (0001677940) (Issuer)

    5/15/26 4:13:11 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kirkby Matthew

    4 - BeyondSpring Inc. (0001677940) (Issuer)

    4/8/26 4:57:26 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fabbio Patrick

    4 - BeyondSpring Inc. (0001677940) (Issuer)

    4/3/26 5:43:32 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BeyondSpring downgraded by Jefferies with a new price target

    Jefferies downgraded BeyondSpring from Buy to Hold and set a new price target of $5.00 from $38.00 previously

    12/2/21 5:17:19 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring downgraded by B of A Securities with a new price target

    B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously

    12/2/21 4:49:29 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring downgraded by William Blair

    William Blair downgraded BeyondSpring from Outperform to Mkt Perform

    12/1/21 10:55:31 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Leadership Updates

    Live Leadership Updates

    View All

    BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

    Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully dedicated executive leaderDr. Jiangwen (Jen) Majeti, PhD, MBA, current BeyondSpring Director, appointed Vice Chairman — deepening Board-level governance and providing strategic continuityMin Qiu appointed Chief Executive Officer with a clear mandate: execute DUBLIN-4, extend Plinabulin's scientific optionality, and build BeyondSpring's global partner and investor baseNa Li appointed Chief Financial Officer to strengthen BeyondSpring's financial position and support capital mark

    6/4/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

    NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawa

    10/23/23 7:45:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

    Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the "Company"), a BeyondSpring (NASDAQ:BYSI) subsidiary and global research company focused on harnessing and engineering "molecular glues," a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 5

    6/20/23 8:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Financials

    Live finance-specific insights

    View All

    BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

    AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline

    5/13/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Reports 2025 Year-End Financial Results

    Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors progressed after first line therapy — DUBLIN-3 study results published in The Lancet Respiratory Medicine Confirmatory Trial Planned: Based on DUBLIN-3 Phase 3 data and US FDA discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient population progressed on immune checkpoint inhibitors (NCT07361484)Overcoming Immunotherapy Resistance: Early clinical data at MD A

    3/25/26 8:30:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

    Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI

    3/27/25 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    2/14/24 4:30:59 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    4/7/23 5:02:43 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care